We're proud to receive a 2025 CDMO Leadership Award in the “Small Molecule Dosage Form - Global" category.
With a growing pipeline of both traditional and regenerative biopharmaceutical drugs and increasing cadence of approvals for novel biologics and biosimilars, there is a need now more than ever for readily available solutions that will translate the promise of a remarkable discovery into a successful therapy.
This webinar showcases how Thermo Fisher Scientific is leveraging infrastructure investments and innovation to deliver platform and bespoke solutions meant to accelerate biologics development.